Skip to content

This site is intended for UK healthcare professionals only. If you are not a UK healthcare professional, please visit our dedicated site for more information at www.beigene.co.uk

BRUKINSA logo

DESIGNED TO BE DIFFERENT

by minimising off-target effects in the treatment of B-cell malignancies1-4

The development of BRUKINSA began in 2012 as a collaboration between the medical, biochemistry, discovery biology, and in vivo pharmacology departments at BeiGene. The team screened more than 3,000 compounds to find the molecule with the highest therapeutic potential: BGB-3111 (the 3,111th compound screened), later named zanubrutinib.5

Like other covalent BTK inhibitors, BRUKINSA is a small molecule that binds irreversibly to cysteine 481 in the ATP binding pocket of BTK. However, its molecular structure offers a distinct pharmacokinetic profile.1,3,5,6

The only BTK inhibitor that provides up to 100% occupancy (median steady-state)1

  • Occupancy in PBMCs was 100% with both BID and QD dosing
  • Occupancy in lymph nodes was 100% with BID and 94% with QD dosing

The clinical significance of in vivo and in vitro studies has not been established. Mechanism of action statements are not meant to imply efficacy or safety.

What is Brukinsa

Adapted from Tam, et al. 2021.1

Scroll left and right to see more

The IC50 is the drug concentration that achieves 50% inhibtion.21

BRUKINSA kinase selectivity3

A KinMap dendrogram showing the selectivity profile of BRUKINSA. Larger circles indicate greater inhibition.

Scroll left and right to see more

It is only recommended if the company provides it according to the commercial agreement or PAS arrangement8–10,14–16

NICE recommendations for BTK inhibitor monotherapy in CLL, R/R WM and R/R MZL8–13

NICE recommends BRUKINSA monotherapy as a treatment option:8-10

  • In adult patients with untreated CLL and there is a 17p deletion or TP53 mutation, or there is no 17p deletion or TP53 mutation and FCR or BR is unsuitable, or in R/R disease
  • In adult patients with WM who have had at least one treatment, only if BR is also suitable
  • In adult patients with MZL who have received at least one prior anti-CD20-based therapy

SMC acceptance for BTK inhibitor monotherapy in CLL, WM and R/R MZL14–19

SMC recommendations for BRUKINSA:14-16

BRUKINSA monotherapy is accepted as an option for treating:

  • Adult patients with CLL, in whom chemo-immunotherapy is unsuitable
  • WM in adults who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy
  • Adult patients with MZL who have received at least one prior anti-CD20-based therapy
Select an indication to learn more about BRUKINSA: